Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Stockerau – page 8

880 clinical trials in Stockerau, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Stockerau at a glance
880
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

880 trials in Stockerau

Open in trial search

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RO7589655
  • Sponsor:F. Hoffmann-La Roche AG

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen - Cilag International

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Myopia

Recruiting

Safety and Efficacy of Sodium Phenylbutyrate Eye Drops in Children with Myopia

Investigational
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Sodium Phenylbutyrate
  • Sponsor:Laboratoires Thea

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Belatacept Dose Reduction Safety in Kidney Transplant Recipients with a Well-Matched Donor

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Belatacept
  • Sponsor:Medical University Of Vienna

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Deciphera Pharmaceuticals Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Stockerau

What the registry says about research in the country

01 Metabolic Health Studies

Innovative research focusing on obesity and cardiovascular health, examining new therapeutic approaches for weight management and associated cardiovascular risks.

  • Cardiovascular Safety Assessment
  • Weight Management
  • Metabolic Disease Prevention

Studies aim to evaluate cardiovascular outcomes in individuals with overweight or obesity conditions.

02 Autoimmune Research

Clinical investigations targeting Sjögren's Syndrome, evaluating novel biological treatments to improve patient outcomes and disease management.

  • Disease Activity Assessment
  • Immunological Response
  • Symptom Management

Research focuses on measuring treatment efficacy through standardized disease activity scores.

03 Therapeutic Innovations

Advanced clinical research examining novel therapeutic compounds for chronic conditions, with emphasis on safety and efficacy measurements.

  • Drug Safety Profiles
  • Treatment Effectiveness
  • Patient Response Monitoring

Studies incorporate comprehensive safety monitoring and outcome assessment protocols.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.